Markel vs. Skyward: Which Specialty Insurance Stock Is a Better Buy in 2026?

Markel reported FY 2025 revenue of nearly $16.6 billion and net income of about $2.1 billion, while Skyward Specialty posted faster growth with revenue up 23% to nearly $1.4 billion and net income rising to just over $170 million. The article favors Skyward on valuation, with a 9.5x forward P/E versus Markel's 16.3x, and highlights Skyward's revenue momentum and Apollo acquisition as positive catalysts. Markel remains financially solid but faces headwinds from broker concentration, weak insurance premiums, and equity-market sensitivity, and it does not pay a dividend.

Analysis

The market is effectively choosing between two different earnings engines: Markel is a long-duration balance sheet story with meaningful mark-to-market sensitivity, while Skyward is a nearer-term compounding story where premium growth can outrun loss ratio drift as long as pricing stays rational. In that setup, the cleaner second-order winner is actually the ecosystem around niche commercial insurance: brokers, MGA-like distribution, and reinsurance partners gain leverage when underwriters need speed and capacity more than broad brand. That favors the operator with the highest underwriting momentum, but it also compresses room for error if catastrophe volatility reappears.

The key hidden risk on Markel is not just underwriting softness; it is that a large equity book turns the company into a quasi-long-duration equity factor with an insurance wrapper. That means a flat or choppy equity tape can suppress reported compounding even if underwriting remains stable, and the absence of a dividend removes the natural shareholder-support mechanism that often cushions insurer reratings. In contrast, Skyward’s growth multiple is more fragile to any sign that its niche expansion is coming from price rather than unit economics, because the market will quickly de-rate a growth insurer whose reinsurance cost or loss picks start to lag.

The consensus seems to be underestimating the earnings quality gap. Skyward’s lower valuation is not free; it is partly compensating investors for concentration in volatile niches and dependence on external capital support, but if loss experience stays controlled for another 2-3 quarters, the stock can re-rate before the 2026 growth numbers are fully visible. Markel could work only if its investment portfolio and underwriting both reaccelerate at the same time — a high bar — so the better asymmetry is to own the growth name while hedging the broader specialty insurance beta.

Key Decisions for Investors

• Long SKWD outright on a 3-6 month horizon; thesis is multiple expansion on sustained top-line growth, with upside if forward revenue growth stays above 25% and the market starts rewarding compounding over quality-of-earnings skepticism.
• Short/underweight BRK.B vs. long SKWD as a relative-value pair over 6-12 months; the hedge reduces market beta while expressing a preference for underwriting growth over asset-heavy capital allocation, with risk that a broad equity rally lifts both but favors BRK.B less on multiple.
• If trading options, buy SKWD calls or call spreads into the next 1-2 quarters and finance with a small BRK.B short or sector hedge; the setup is asymmetric because the stock can re-rate on visibility before fundamentals fully inflect, while downside is more gradual unless losses spike.
• Avoid initiating a fresh long in Markel until there is evidence of either equity portfolio upside or underwriting reacceleration over 2 consecutive quarters; the risk/reward is poor because multiple support is limited without a dividend or a clear catalyst.
• For risk control, pair any SKWD long with monitoring on reinsurance spreads and catastrophe headlines; if pricing softens or loss ratios worsen for 1 quarter, trim aggressively because the de-rating risk is faster than the upside rerate.